For instance, large-scale meta-analyses of pembrolizumab and nivolumab have consistently shown superior ORR and DCR compared to chemotherapy in both first-line and second-line settings for NSCLC, particularly in patients with high PD-L1 expression (Wang et al., 2019b; Reck et al., 2016). The gene discussed is CD274; the disease is non-small cell lung carcinoma.